[评论] 缩小感染HIV青少年的死亡率差距
摘要
尽管抗逆转录病毒治疗（ART）取得了重大进展，但与一般人群相比，感染HIV的青少年仍然存在巨大的死亡率差距。1 青少年获得ART的机会落后于成人——青少年约为60%，而总体为78%。2 对于确实接受了救命治疗的青少年，许多感染HIV的青少年对每日ART的依从性不稳定，导致病毒未抑制，增加临床失败和死亡的风险。3 由M
English
Despite major advancements in antiretroviral therapy (ART), a substantial mortality gap remains for adolescents living with HIV compared with the general population.1 Adolescents’ access to ART lags behind that of adults—approximately 60% for adolescents compared with 78% overall.2 For those who do receive life-saving therapy, inconsistent adherence to daily ART among many adolescents with HIV leads to viral non-suppression, increasing risks of clinical failure and death.3 The LATA trial, reported in The Lancet by Mutsa Bwakura-Dangarembizi and colleagues, was conducted in the four African countries in which most of the world's 1·57 million adolescents living with HIV reside; it offers hope that the challenges of adhering to daily oral ART for adolescents can be mitigated with longer actin